أرسل هذا في رسالة قصيرة: Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

  _  __     ___      _____    __   __    ____    
 | |/ //   / _ \\   / ____||  \ \\/ //  |  _ \\  
 | ' //   | / \ || / //---`'   \ ` //   | |_| || 
 | . \\   | \_/ || \ \\___      | ||    | .  //  
 |_|\_\\   \___//   \_____||    |_||    |_|\_\\  
 `-` --`   `---`     `----`     `-`'    `-` --`